Incidence and clinical implication of tumor cavitation in patients with advanced non-small cell lung cancer induced by Endostar, an angiogenesis inhibitor

Thoracic Cancer
Chun HuangKai Li

Abstract

Antiangiogenesis plays a key role in the treatment of non-small lung cancer (NSCLC). We observed the cavitation of lesions in patients with stage IIIB/IV NSCLC treated with Endostar and vinorelbine-cisplatin (NP) chemotherapy, and evaluated the imaging characteristics and clinical outcome of patients who developed tumor cavitation. Our study included 105 untreated NSCLC patients who received Endostar in combination with NP chemotherapy at the Tianjin Lung Cancer Center. Chest computed tomography (CT) was performed to evaluate the efficacy every two cycles. The number of activated circulating endothelial cells (aCECs) was measured by flow cytometry. Rates of tumor cavitation were documented and their clinical CT imaging data were analyzed. Tumor cavitation occurred in 11 of the 105 (10.5%) patients treated with Endostar and NP. The response rates were 37.2% (35/94) in patients without cavitation, 27.3% (3/11) evaluated by Response Evaluation Criteria in Solid Tumors, and 100.0% (11/11) if evaluated by an alternate method in patients who developed cavitation. Three of the 11 cases with cavitation had a centrally located tumor. No patients had hemoptysis or any other severe side effects. Compared with patients not developing cavit...Continue Reading

References

Dec 1, 1980·AJR. American Journal of Roentgenology·J H WoodringV P Chuang
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstJames L Abbruzzese
Apr 4, 2003·Advances in Experimental Medicine and Biology·Patrizia MancusoFrancesco Bertolini
Dec 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L V BeerepootE E Voest
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David H JohnsonFairooz Kabbinavar
Jan 22, 2005·Acta Pharmacologica Sinica·Hai-feng SongZhong-ming Tang
Apr 14, 2005·Pacing and Clinical Electrophysiology : PACE·Owen P Faris, Mitchell J Shein
Jan 18, 2006·Thrombosis and Haemostasis·Bruno DelormeFrançoise Dignat-George
Feb 9, 2006·Nature Biotechnology·Hepeng Jia, Jim Kling
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Apr 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Edith M MaromAmir Onn
Dec 3, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Simon J CrabbScott A Laurie
Feb 24, 2010·Microvascular Research·Patrizia Mancuso, Francesco Bertolini
Aug 3, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Baoshan CaoJun Ren
Oct 6, 2012·Cancer Control : Journal of the Moffitt Cancer Center·Joanne MortimerSumanta K Pal
Aug 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hyun-Kyung YuTae Jin Kim
Aug 27, 2013·Lancet·Martin ReckKlaus F Rabe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.